Jay P. Powers

2.8k total citations
66 papers, 1.7k citations indexed

About

Jay P. Powers is a scholar working on Oncology, Physiology and Immunology. According to data from OpenAlex, Jay P. Powers has authored 66 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 18 papers in Physiology and 18 papers in Immunology. Recurrent topics in Jay P. Powers's work include Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (11 papers) and Chemokine receptors and signaling (11 papers). Jay P. Powers is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Nanoplatforms for cancer theranostics (11 papers) and Chemokine receptors and signaling (11 papers). Jay P. Powers collaborates with scholars based in United States, Switzerland and Canada. Jay P. Powers's co-authors include Juan C. Jaén, Thomas J. Schall, Nigel P.C. Walker, Zhulun Wang, Scott D. Rychnovsky, Lisa Seitz, Daniel J. Dairaghi, Mark E.T. Penfold, Linda Ertl and Penglie Zhang and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Jay P. Powers

62 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay P. Powers United States 21 667 455 400 333 267 66 1.7k
Sylvain Cottens Switzerland 16 813 1.2× 1.8k 4.1× 387 1.0× 309 0.9× 148 0.6× 26 3.5k
Guido Hartmann Switzerland 22 313 0.5× 1.4k 3.1× 570 1.4× 268 0.8× 137 0.5× 38 3.4k
Paul P. Tamburini United States 27 244 0.4× 937 2.1× 538 1.3× 83 0.2× 51 0.2× 48 2.1k
Richard Sedrani Switzerland 16 148 0.2× 783 1.7× 237 0.6× 343 1.0× 88 0.3× 23 1.6k
Paul Nimmer United States 8 315 0.5× 1.8k 3.9× 665 1.7× 222 0.7× 129 0.5× 11 2.4k
Erkan Baloglu United States 30 298 0.4× 1.9k 4.1× 1.2k 3.0× 319 1.0× 210 0.8× 85 3.0k
Krikor Bijian Canada 22 169 0.3× 553 1.2× 162 0.4× 122 0.4× 83 0.3× 40 1.2k
Manik Chatterjee Germany 32 424 0.6× 1.7k 3.8× 844 2.1× 154 0.5× 113 0.4× 87 2.7k
David Uehling Canada 27 411 0.6× 2.3k 5.0× 800 2.0× 756 2.3× 155 0.6× 46 3.2k
Gabriele Weitz‐Schmidt Switzerland 23 753 1.1× 965 2.1× 318 0.8× 357 1.1× 102 0.4× 48 2.5k

Countries citing papers authored by Jay P. Powers

Since Specialization
Citations

This map shows the geographic impact of Jay P. Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay P. Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay P. Powers more than expected).

Fields of papers citing papers by Jay P. Powers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay P. Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay P. Powers. The network helps show where Jay P. Powers may publish in the future.

Co-authorship network of co-authors of Jay P. Powers

This figure shows the co-authorship network connecting the top 25 collaborators of Jay P. Powers. A scholar is included among the top collaborators of Jay P. Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay P. Powers. Jay P. Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
DiRenzo, Daniel, Joanne B.L. Tan, Dillon H. Miles, et al.. (2019). Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. Cancer Immunology Research. 7(2_Supplement). A162–A162. 7 indexed citations
2.
Seitz, Lisa, Manmohan R. Leleti, Jay P. Powers, et al.. (2018). Final results of the phase I study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response. Annals of Oncology. 29. viii665–viii665. 2 indexed citations
3.
Seitz, Lisa, Lixia Jin, Manmohan R. Leleti, et al.. (2018). Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Investigational New Drugs. 37(4). 711–721. 48 indexed citations
4.
Schindler, Ulrike, Joanne B.L. Tan, Annette Becker, et al.. (2017). Abstract 2640: Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-cancer targets in the ATP/adenosine signaling pathway. Cancer Research. 77(13_Supplement). 2640–2640. 1 indexed citations
5.
6.
Jaén, Juan C., Jay P. Powers, Ada Chen, et al.. (2016). Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors. Cancer Immunology Research. 4(11_Supplement). PR10–PR10. 2 indexed citations
7.
Wang, Zhulun, Daqing Sun, Sheree Johnstone, et al.. (2015). Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4. Bioorganic & Medicinal Chemistry Letters. 25(23). 5546–5550. 6 indexed citations
8.
Bekker, Pirow, Karen Ebsworth, Matthew J. Walters, et al.. (2015). CCR9 Antagonists in the Treatment of Ulcerative Colitis. Mediators of Inflammation. 2015(1). 628340–628340. 18 indexed citations
9.
Sullivan, Timothy J., Zhenhua Miao, Daniel J. Dairaghi, et al.. (2013). CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. American Journal of Physiology-Renal Physiology. 305(9). F1288–F1297. 76 indexed citations
10.
Miao, Zhenhua, Yu Wang, Jay P. Powers, et al.. (2013). The CCR4 antagonist CCX6239 for the treatment of allergic airways disease. European Respiratory Journal. 42(Suppl 57). 3535–3535. 1 indexed citations
11.
Walters, Matthew J., Karen Ebsworth, Timothy J. Sullivan, et al.. (2013). CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. Immunology Letters. 151(1-2). 44–47. 5 indexed citations
12.
Rew, Yosup, Xiaodong He, Juan C. Jaén, et al.. (2012). Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(11). 3786–3790. 5 indexed citations
13.
Zabel, Brian A., Yu Wang, Susanna Lewén, et al.. (2009). Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands. The Journal of Immunology. 183(5). 3204–3211. 245 indexed citations
14.
McMinn, Dustin L., Yosup Rew, Athena Sudom, et al.. (2009). Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(5). 1446–1450. 18 indexed citations
15.
Rew, Yosup, Dustin L. McMinn, Zhulun Wang, et al.. (2009). Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(6). 1797–1801. 23 indexed citations
16.
Tu, Hua, Jay P. Powers, Jinsong Liu, et al.. (2008). Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorganic & Medicinal Chemistry. 16(19). 8922–8931. 30 indexed citations
17.
Powers, Jay P., Shyun Li, Juan C. Jaén, et al.. (2006). Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorganic & Medicinal Chemistry Letters. 16(11). 2842–2845. 99 indexed citations
18.
Cushing, Timothy D., John A. Flygare, Jay P. Powers, et al.. (2006). Discovery of a novel series of inhibitors of human cytomegalovirus primase. Bioorganic & Medicinal Chemistry Letters. 16(18). 4879–4883. 5 indexed citations
19.
Lee, Gary, Derek E. Piper, Zhulun Wang, et al.. (2006). Novel Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerases. Journal of Molecular Biology. 357(4). 1051–1057. 34 indexed citations
20.
Wang, Zhulun, Jinsong Liu, Athena Sudom, et al.. (2006). Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper. Structure. 14(12). 1835–1844. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvain Cottens Breakdown of academic impact, for papers by Guido Hartmann Breakdown of academic impact, for papers by Paul P. Tamburini Breakdown of academic impact, for papers by Richard Sedrani Breakdown of academic impact, for papers by Paul Nimmer Breakdown of academic impact, for papers by Erkan Baloglu Breakdown of academic impact, for papers by Krikor Bijian Breakdown of academic impact, for papers by Manik Chatterjee Breakdown of academic impact, for papers by David Uehling Breakdown of academic impact, for papers by Gabriele Weitz‐Schmidt
Rankless by CCL
2026